- InVivo Therapeutics Holdings Corp NVIV announced topline results from its INSPIRE 2.0 study of Neuro-Spinal Scaffold, a bioresorbable scaffold-based device for acute spinal cord injuries (SCI).
- The study did not meet its primary endpoint, which was assessed by the proportion of treated patients achieving an improvement of at least one American Spinal Injury Association (ASIA) Impairment Scale (AIS) grade at six months post-scaffold implantation versus a control group that received standard of care surgery.
- InVivo management will conduct a full assessment of the study data set and will share its findings in a peer-reviewed medical venue later.
- The company will also evaluate its strategic options and update corporate direction when appropriate.
- Price Action: NVIV shares traded lower by 50% at $1.05 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
